Intelligence · Clinical pipeline
Oncology R&D Pipeline
Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.
Quick answer
Oncology: NovaPharmaNews indexes 5,539 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.
Top sponsors
- First People's Hospital 474 programs
- Chinese Academy of 400 programs
- United Therapeutics Europe 219 programs
- George Institute for 172 programs
- Takeda 163 programs
- HOFFMANN-LA ROCHE 144 programs
- AstraZeneca 143 programs
- MSD Merck Sharp 131 programs
- Regeneron UK 128 programs
- Anaxis Pharma 125 programs
- Telethon Foundation 113 programs
- Novartis India 110 programs
Pipeline programs
-
Selinexor
Karyopharm Therapeutics Inc
Acute Myeloid Leukemia (AML)
3 trials -
Selinexor
Karyopharm Therapeutics Inc
Breast Cancer
1 trial -
Selinexor
Karyopharm Therapeutics Inc
Leukemia
2 trials -
Selinexor
Karyopharm Therapeutics Inc
Acute Myeloid Leukemia
1 trial -
Selinexor
Karyopharm Therapeutics Inc
Relapsed or Refractory Diffuse Large B-Cell Lymphoma
1 trial -
Selinexor
Karyopharm Therapeutics Inc
Metastatic Colorectal Cancer
1 trial -
Selinexor
The First People's Hospital of Lianyungang
Acute Myeloid Leukemia (Relapsed/Refractory)
1 trial -
Selinexor
Karyopharm Therapeutics Inc
Locally Advanced Unresectable or Metastatic Melanoma
1 trial -
Selinexor
Karyopharm Therapeutics Inc
Solid Tumor Malignancy
1 trial -
Selinexor
Karyopharm Therapeutics Inc
Recurrent Small Cell Lung Carcinoma
1 trial -
Selinexor
Karyopharm Therapeutics Inc
Diffuse Large B-cell Lymphoma
1 trial -
Selinexor
Karyopharm Therapeutics Inc
Prostate Cancer
1 trial -
Selinexor
Karyopharm Therapeutics Inc
Acute Myeloid Leukemia (Relapsed/Refractory)
1 trial -
Selinexor
Karyopharm Therapeutics Inc
Ovarian Carcinoma
1 trial -
Selinexor
Karyopharm Therapeutics Inc
Carcinoma, Neuroendocrine
1 trial -
Selinexor
Hospital Authority, Hong Kong
Acute Myeloid Leukemia, Adult
1 trial -
Selinexor
Karyopharm Therapeutics Inc
Non-small Cell Lung Cancer
1 trial -
Selinexor
Karyopharm Therapeutics Inc
Peripheral T-cell Lymphoma (PTCL)
1 trial -
Selinexor (KPT-330)
Karyopharm Therapeutics Inc
Squamous Cell Carcinoma
1 trial -
Selinexor 100 mg
Karyopharm Therapeutics Inc
Non-Small Cell Lung Carcinoma (NSCLC)
1 trial -
Selpercatinib
Eli Lilly and Company
Medullary Thyroid Cancer
1 trial -
Selpercatinib Monotherapy
United Therapeutics Europe Ltd
Differentiated Thyroid Cancer
1 trial -
Selumetinib
United Therapeutics Europe Ltd
Metastatic Thyroid Gland Carcinoma
1 trial -
Selumetinib
United Therapeutics Europe Ltd
Malignant Peripheral Nerve Sheath Tumors
1 trial -
Serplulimab
The First People's Hospital of Lianyungang
HER2-positive Gastric Cancer
1 trial -
Serplulimab
The First People's Hospital of Lianyungang
Colorectal Cancer (Diagnosis)
1 trial -
Serplulimab
The First People's Hospital of Lianyungang
Gastric Cancer
1 trial -
Sigvotatug vedotin, PF-08634404
Pfizer Australia Pty Ltd
Advanced Solid Tumors
1 trial -
Sindillimab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Non-small Cell Lung Cancer
1 trial -
Sintilimab
The First People's Hospital of Lianyungang
Nasopharyngeal Carcinoma (NPC)
1 trial -
Sintilimab
The First People's Hospital of Lianyungang
Esophageal Squamous Cell Carcinoma
1 trial -
Sintilimab
The First People's Hospital of Lianyungang
Ovarian Clear Cell Carcinoma
1 trial -
Sintilimab
The First People's Hospital of Lianyungang
Multiple Primary Lung Cancer
1 trial -
Sintilimab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Non-small Cell Lung Cancer Stage III
1 trial -
Sintilimab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Renal Cell Carcinoma
1 trial -
Sintilimab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Lung Neoplasms
1 trial -
Sintilimab
The First People's Hospital of Lianyungang
Carcinoma
1 trial -
Sintilimab
The First People's Hospital of Lianyungang
Small Cell Lung Cancer Limited Stage
1 trial -
Sintilimab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Non-small Cell Lung Cancer
1 trial -
Sintilimab (approved)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Hepatocellular Carcinoma (HCC)
1 trial -
Sintilimab Combined with Platinum-containing Chemotherapy
The First People's Hospital of Lianyungang
Non-small Cell Lung Cancer
1 trial -
Sintilimab in combination with Multimodality Radiotherapy
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Nasopharyngeal Carcinoma
1 trial -
Sintilimab injection plus Inlyta treatment
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Carcinoma, Renal Cell
1 trial -
Sintilimab with Interleukin-2+CAPOX
The First People's Hospital of Lianyungang
Locally Advanced Rectal Adenocarcinoma
1 trial -
Sintilimab,nab-paclitaxel and tegio
The First People's Hospital of Lianyungang
Gastric Cancer
1 trial -
Sitravatinib
BeiGene
Carcinoma, Hepatocellular
1 trial -
Sm-EDTMP
Jazz Pharmaceuticals Ireland Limited
Metastatic Osteosarcoma
1 trial -
Sodium Cridanimod
Xenetic Biosciences
Endometrial Cancer
1 trial
Frequently asked questions
How many oncology pipeline programs are tracked?
5,539 programs match this therapeutic area based on indication text, program name, and registry metadata.
Where does pipeline data come from?
ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.